London, United Kingdom–based global venture capital firm Index Ventures has launched a €150m fund dedicated to making investments in the life sciences sector.
Backers include Index’s existing limited partners and two companies, GlaxoSmithKline (GSK) and the venture capital affiliate of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen). With the investment, the two global pharmaceutical companies will share their expertise by participating in the scientific advisory board (SAB) of the fund, which also include five Index Ventures-appointed executives:
– Francesco De Rubertis,
– Kevin Johnson,
– Michele Ollier,
– Roman Fleck, and
– Remy Luthringer.
The firm will consider opportunities across Europe, primarily, but also across the USA, with assets that have first-in-class or best-in-class mechanisms of action and target areas of unmet medical need.